T1加权动态对比增强MR灌注成像可区分接受放射治疗的脊柱转移瘤的治疗成功与失败
回顾性研究纳入49例接受放射治疗的脊柱转移瘤患者,比较动态对比增强MR灌注参数变化与临床结局的相关性。成功组血浆容积降低幅度大于失败组(-57.3% vs +88.2%,P<.001)。血浆容积判断治疗成功的敏感度为91%、特异度为87%,尺寸测量敏感度为82%、特异度为47%。
要点
- 血浆容积降低幅度在治疗成功组大于失败组(-57.3% vs +88.2%,P<.001)。
- 血浆容积判断治疗成功的敏感度91%、特异度87%,尺寸测量敏感度82%、特异度47%。
- 血浆容积特异度高于传统尺寸测量,提示动态对比增强MR灌注成像有助于区分治疗成功与失败。
核心结论
- 血浆容积判断治疗成功的特异度高于传统尺寸测量,提示动态对比增强MR灌注成像是有力工具,可区分脊柱转移瘤放射治疗的成功与失败。
研究设计与样本
- 回顾性研究纳入49例接受放射治疗的脊柱转移瘤患者(平均年龄63岁,SD 13岁;29例男性),均行动态对比增强MR灌注成像;放射治疗与随访动态对比增强MR灌注成像的中位间隔为62天;分为临床成功组38例和失败组11例。
诊断标准与关键数值
- 失败定义为PET复发(n=5)、活检证实复发(n=1)或肿瘤尺寸增大(n=7),无上述表现定义为临床成功;血浆容积判断治疗成功的敏感度为91%(10/11;95% CI,82%-97%),特异度为87%(33/38;95% CI,73%-94%);尺寸测量判断治疗成功的敏感度为82%(9/11;95% CI,67%-90%),特异度为47%(18/38;95% CI,37%-67%);成功组血浆容积降低-57.3%,失败组血浆容积增加+88.2%(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Current imaging techniques have difficulty differentiating treatment success and failure in spinal metastases undergoing radiation therapy. This study investigated the correlation between changes in dynamic contrast-enhanced MR imaging perfusion parameters and clinical outcomes following radiation therapy for spinal metastases. We hypothesized that perfusion parameters will outperform traditional size measurements in discriminating treatment success and failure.
MATERIALS AND METHODS: This retrospective study included 49 patients (mean age, 63 [SD, 13] years; 29 men) with metastatic lesions treated with radiation therapy who underwent dynamic contrast-enhanced MR imaging. The median time between radiation therapy and follow-up dynamic contrast-enhanced MR imaging was 62 days. We divided patients into 2 groups: clinical success (n = 38) and failure (n = 11). Failure was defined as PET recurrence (n = 5), biopsy-proved (n = 1) recurrence, or an increase in tumor size (n = 7), while their absence defined clinical success. A Mann-Whitney U test was performed to assess differences between groups.
RESULTS: The reduction in plasma volume was greater in the success group than in the failure group (-57.3% versus +88.2%, respectively; P < .001). When we assessed the success of treatment, the sensitivity of plasma volume was 91% (10 of 11; 95% CI, 82%-97%) and the specificity was 87% (33 of 38; 95% CI, 73%-94%). The sensitivity of size measurements was 82% (9 of 11; 95% CI, 67%-90%) and the specificity was 47% (18 of 38; 95% CI, 37%-67%).
CONCLUSIONS: The specificity of plasma volume was higher than that of conventional size measurements, suggesting that dynamic contrast-enhanced MR imaging is a powerful tool to discriminate between treatment success and failure.
引用
- Behar M, Peck KK, Yildirim O, et al. T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy. AJNR Am J Neuroradiol. 2023. PMID: 38049990. doi:10.3174/ajnr.A8057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。